Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1412)	2/9/1999 6:43:00 PM
From: Anthony Wong	Respond to of 1722

Monsanto Co. Reiterated 'Buy' at DLJ Bloomberg News February 9, 1999, 4:40 p.m. ET Princeton, New Jersey, Feb. 9 (Bloomberg Data) -- Monsanto Co. (MTC US) was reiterated ''buy'' by analyst William R. Young at Donaldson Lufkin & Jenrette Securities Corp. The 12-month target price is $58.00 per share.

To: Anthony Wong who wrote (1412)	2/9/1999 6:48:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Pfizer Inc. Reiterated Near-Term 'Buy' at Merrill Bloomberg News February 9, 1999, 11:25 a.m. ET Princeton, New Jersey, Feb. 9 (Bloomberg Data) -- Pfizer Inc. (PFE US) was reiterated near-term ''buy'' by analyst Steven C. Tighe at Merrill Lynch & Co. The long-term rating was also reiterated ''buy.'' -- Michael O. Donohue in Princeton, New Jersey, (609)279-3156

To: Anthony Wong who wrote (1412)	2/9/1999 6:49:00 PM
From: Anthony Wong	Respond to of 1722

Eli Lilly Receives Initial Approval to Sell Gemzar in Japan Bloomberg News February 9, 1999, 6:12 a.m. ET Eli Lilly Receives Initial Approval to Sell Gemzar in Japan Tokyo, Feb. 9 (Bloomberg) -- Eli Lilly & Co.'s Japanese unit received initial approval to sell its anti-cancer agent Gemzar in Japan, said the country's Ministry of Health and Welfare. Gemzar (gemcitabine), which was approved by a ministry panel to treat non-small-cell lung cancer in Japan, had sales totaling $95.1 million in the fourth quarter, up 78 percent from the fourth quarter a year earlier. ''It may be too early to think Gemzar will become a big drug in Japan because the filing is only for one kind of cancer,'' said Kenji Masuzoe, analyst at Deutsche Securities in Japan. The drug is approved in more than 65 countries for non- small-cell lung, pancreatic and other types of cancer. In 1998 Gemzar's global sales increased 76 percent, to $306.8 million, Eli Lilly said. Gemzar is being studied for the treatment of bladder cancer, breast cancer and ovarian cancer. Other drugs which received initial approval include Banyu Pharmaceutical Co.'s glaucoma eyedrop treatment Trusopt (dorzolamide). The drug was developed by Merck & Co., which has Trusopt sales of $280 million a year, said Masuzoe. Of 19 drugs reviewed by today's health ministry panel, 18 received initial approval, said Haruo Akagawa, an official of the health ministry's Pharmaceutical and Medial Safety Bureau. The other, Fujisawa Pharmaceutical Co.'s anti depressant Lubox, needs to be scrutinized by a standing committee of Central Pharmaceutical Affairs Council, the panel said. Lubox (flubozamine) was developed by Brussels-based Solvay SA, Belgium's No. 1 chemicals and drugs maker. If it gets final approval from the standing committee, it'll be the first selective serotonin re-uptake inhibitor, or SSRI, to become available in Japan, Deutsche Securities' Masuzoe said. Eli Lilly's Prozac is the biggest selling SSRI. SSRIs manage depression but can depress sexual drive and cause insomnia. --Ryoko Imaizumi in the Tokyo newsroom (813) 3201-8378 /ja